ClinicalTrials.gg
CompletedNCT00335452CURRENT/OASIS7Updated Nov 18, 2010Results posted

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

A Phase 3 interventional study of Clopidogrel and acetylsalicyclic acid (ASA) in Acute Coronary Disease and Angina Unstable, sponsored by Sanofi. Completed at 38 sites in 38 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-18.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25,086
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Angina, Unstable with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Angina, Unstable · United States.

Enrollment
2nd of 39
25,086 · median 305
Started
2006
with 5 others
Phase 3
11 of 58
none open now
Registered
15th of 58
by date
Lead sponsor
2 of 58
Sanofi

Among the 58 studies in Angina, Unstable with a site in United States, this one is the 2nd largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2006, is one of 11 in phase 3, and was the 15th registered.

Angina, Unstable

330 studies on the registry are indexed under Angina, Unstable; 44 are open to participants now.

Browse Angina, Unstable studies →

Open to participants now

2 of the 58 studies in Angina, Unstable with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Angina, Unstable studies recruiting now, 29 (85%) set no upper age limit and 3 (9%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Angina, Unstable with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a percutaneous coronary intervention (PCI).

03

Conditions studied

  • Acute Coronary Disease
  • Angina Unstable

Browse trials for

Keywords

  • platelet aggregation inhibitors
  • acute coronary disease
  • percutaneous coronary
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with acute coronary disease with clinical symptoms and at least changes or cardiac enzymes elevated

Exclusion criteria

Exclusion Criteria:

  • Use of anticoagulants within 10 days with an (INR) > 1.5 or planned use during the hospitalisation period
  • Administration of clopidogrel > 75 mg prior to randomization
  • to clopidogrel or aspirin
  • Active bleeding or significant risk of bleeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
25,086 participants (actual)

Study arms

  • Experimental
    Clopidogrel high dose treatment regimen + ASA high dose

    Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)

  • Experimental
    Clopidogrel high dose treatment regimen + ASA low dose

    Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)

  • Active comparator
    Clopidogrel standard treatment regimen + ASA high dose

    Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)

  • Active comparator
    Clopidogrel standard treatment regimen + ASA low dose

    Drug: Clopidogrel · Drug: acetylsalicyclic acid (ASA)

Interventions

06

What researchers measure

Primary outcomes

  1. First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

    The primary endpoint is the first occurrence of any of the following events: * Cardiovascular death (any death with a clear cardiovascular or unknown cause), * Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal) * Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal) reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC).

    Time frame: 30 days

  2. First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison

    Time frame: 30 days

  3. First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level

    Time frame: 30 days

  4. First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup

    Time frame: 30 days

Secondary outcomes

  1. Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

    Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC.

    Time frame: 30 days

  2. Occurrence of Major Bleeding - ASA Dose Level Comparison

    Time frame: 30 days

07

Results

Posted Oct 7, 2010

Participant flow

25086 patients were enrolled and randomized between June 2006 and August 2009 in 597 sites in 39 countries. Because the observed overall blinded event rate was substantially lower than expected, the number of patients to be enrolled was increased from 18000 to 20000, then to 25000.

Participant flow — Overall Study
MilestoneClopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High Dose
Started6312625462676253
Treated with clopidogrel6271621862286217
Treated with asa6302625162616247
Completed6154610761086122
Not completed158147159131
Withdrew: Death156144158129
Withdrew: Lost to follow-up2312

Outcome measures

PrimaryFirst Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison

The primary endpoint is the first occurrence of any of the following events: * Cardiovascular death (any death with a clear cardiovascular or unknown cause), * Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal) * Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal) reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC).

Time frame:
30 days
Reported as:
Number · participants
First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison
participantsClopidogrel 300/75/75 mg + ASAClopidogrel 600/150/75 mg + ASA
CV death/MI/Stroke557522
- CV death222226
- MI (fatal or not)274237
- Stroke (fatal or not)6159
Statistical analysis
  • Clopidogrel 300/75/75 mg + ASA vs Clopidogrel 600/150/75 mg + ASA · Log Rank · p = 0.3037 (The a priori threshold for statistical significance is ≤0.05.) · Relative risk reduction (%): 6.1 · 95% CI -5.8 to 16.6The relative risk reduction (high dose treatment regimen (600/150/75 mg) versus standard treatment regimen (300/75/75 mg)) is estimated using stratified Cox proportional hazards model controlling for ASA dose level and qualifying condition.
SecondaryOccurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison

Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC.

Time frame:
30 days
Reported as:
Number · participants
Occurrence of Major Bleeding - Clopidogrel Dose Regimen Comparison
participantsClopidogrel 300/75/75 mg + ASAClopidogrel 600/150/75 mg + ASA
Major bleeding255313
- Severe bleeding195236
- Major but not severe bleeding6583
Statistical analysis
  • Clopidogrel 300/75/75 mg + ASA vs Clopidogrel 600/150/75 mg + ASA · Regression, Logistic · p = 0.012 (The a priori threshold for statistical significance is ≤0.05.)logistic regression model including terms for ASA dose level (low or high) and qualifying condition (UA/NSTEMI or STEMI).
PrimaryFirst Occurrence of CV Death / MI / Stroke - ASA Dose Comparison
Time frame:
30 days
Reported as:
Number · participants
First Occurrence of CV Death / MI / Stroke - ASA Dose Comparison
participantsClopidogrel + ASA Low DoseClopidogrel + ASA High Dose
CV death/MI/Stroke546527
- CV death231211
- MI (fatal or not)260251
- Stroke (fatal or not)5565
Statistical analysis
  • Clopidogrel + ASA Low Dose vs Clopidogrel + ASA High Dose · Log Rank · p = 0.6047 (The a priori threshold for statistical significance is ≤0.05.) · Relative risk reduction (%): 3.1 · 95% CI -9.2 to 14.0The relative risk reduction (ASA high dose versus ASA low dose) is estimated using stratified Cox proportional hazards model controlling for Clopidogrel treatment regimen.
PrimaryFirst Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level
Time frame:
30 days
Reported as:
Number · participants
First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level
participantsClopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High Dose
First Occurrence of CV Death / MI / Stroke - Interaction Clopidogrel Treatment Regimen and ASA Dose Level267290282240
Statistical analysis
  • Clopidogrel 300/75/75 mg + ASA Low Dose vs Clopidogrel 600/150/75 mg + ASA Low Dose · Log Rank · p = 0.4579 (The a priori threshold for statistical significance is ≤0.05.) · Relative risk reduction (%): -6.5 · 95% CI -26.0 to 9.9The relative risk reduction (high dose treatment regimen (600/150/75 mg) versus standard treatment regimen (300/75/75 mg)) is estimated using a stratified Cox proportional hazards model controlling for qualifying condition.
  • Clopidogrel 300/75/75 mg + ASA High Dose vs Clopidogrel 600/150/75 mg + ASA High Dose · Log Rank · p = 0.0262 (The a priori threshold for statistical significance is ≤0.05.) · Relative risk reduction (%): 17.6 · 95% CI 2.2 to 30.5The relative risk reduction (high dose treatment regimen (600/150/75 mg) versus standard treatment regimen (300/75/75 mg)) is estimated using a stratified Cox proportional hazards model controlling for qualifying condition.
  • Clopidogrel 300/75/75 mg + ASA Low Dose vs Clopidogrel 300/75/75 mg + ASA High Dose vs Clopidogrel 600/150/75 mg + ASA Low Dose vs Clopidogrel 600/150/75 mg + ASA High Dose · Chi-squared · p = 0.0355 (The a priori threshold for statistical significance is ≤0.05.)Interaction chi-squared test of the Cox proportional hazards model.
PrimaryFirst Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup
Time frame:
30 days
Reported as:
Number · participants
First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison in PCI Subgroup
participantsClopidogrel 300/75/75 mg + ASAClopidogrel 600/150/75 mg + ASA
CV death/MI/Stroke392330
- CV death132130
- MI (fatal or not)225172
- Stroke (fatal or not)3528
Statistical analysis
  • Clopidogrel 300/75/75 mg + ASA vs Clopidogrel 600/150/75 mg + ASA · Log Rank · p = 0.0332 (The a priori threshold for statistical significance is ≤0.05.) · Relative risk reduction (%): 14.7 · 95% CI 1.2 to 26.3The relative risk reduction (high dose treatment regimen (600/150/75 mg) versus standard treatment regimen (300/75/75 mg)) is estimated using a stratified Cox proportional hazards model controlling for ASA dose level and qualifying condition.
SecondaryOccurrence of Major Bleeding - ASA Dose Level Comparison
Time frame:
30 days
Reported as:
Number · participants
Occurrence of Major Bleeding - ASA Dose Level Comparison
participantsClopidogrel + ASA Low DoseClopidogrel + ASA High Dose
Major bleeding285282
- Severe bleeding215216
- Major but not severe bleeding7473
Statistical analysis
  • Clopidogrel + ASA Low Dose vs Clopidogrel + ASA High Dose · Regression, Logistic · p = 0.945 (The a priori threshold for statistical significance is ≤0.05.)Logistic regression model including a term for Clopidogrel treatment regimen (300/75/75 mg or 600/150/75 mg).
Post-hocOccurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison

This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC.

Time frame:
30 days
Reported as:
Number · participants
Occurrence of Stent Thrombosis - Clopidogrel Treatment Regimen Comparison
participantsClopidogrel 300/75/75 mg + ASAClopidogrel 600/150/75 mg + ASA
Stent trombosis200135
- Definite11158
- Probable8977
Statistical analysis
  • Clopidogrel 300/75/75 mg + ASA vs Clopidogrel 600/150/75 mg + ASA · Log Rank · p = 0.0004 (The a priori threshold for statistical significance is ≤0.05.) · Relative risk reduction (%): 32.6 · 95% CI 16.2 to 45.8The relative risk reduction (high dose treatment regimen (600/150/75 mg) versus standard treatment regimen (300/75/75 mg)) is estimated using a stratified Cox proportional hazards model controlling for ASA dose level and qualifying condition.

Adverse events

Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Clopidogrel 300/75/75 mg + ASA Low Dose—322/6,312 (5.1%)0/6,312 (0%)
Clopidogrel 300/75/75 mg + ASA High Dose—329/6,254 (5.3%)0/6,254 (0%)
Clopidogrel 600/150/75 mg + ASA Low Dose—372/6,267 (5.9%)0/6,267 (0%)
Clopidogrel 600/150/75 mg + ASA High Dose—332/6,253 (5.3%)0/6,253 (0%)
Most frequent serious events
Showing 10 of 408
Most frequent serious events
EventClopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High Dose
Operative haemorrhageInjury, poisoning and procedural complications39/631250/625457/626748/6253
Puncture site haemorrhageGeneral disorders17/631221/625422/626731/6253
PneumoniaInfections and infestations21/631211/625422/626716/6253
Post procedural haemorrhageInjury, poisoning and procedural complications12/631216/625418/62676/6253
Renal failure acuteRenal and urinary disorders11/63129/625418/626710/6253
Pericardial haemorrhageCardiac disorders15/631212/625418/626711/6253
Gastrointestinal haemorrhageGastrointestinal disorders13/631212/625415/626715/6253
Pulmonary embolismRespiratory, thoracic and mediastinal disorders5/63127/62545/626710/6253
Vascular pseudoaneurysmInjury, poisoning and procedural complications7/63128/62547/62679/6253
Retroperitoneal haemorrhageGastrointestinal disorders2/63124/62549/62678/6253

Baseline characteristics

Age Continuous
Age Continuous(years)Clopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High DoseTotal
Mean61.3 ± 11.761.5 ± 11.761.2 ± 11.861.4 ± 11.961.3 ± 11.8
Age, Customized
Age, Customized(participants)Clopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High DoseTotal
< 65 years379237403787373515054
65 - 74 years15731576154315436235
≥ 75 years9479379379753796
Missing01001
Sex: Female, Male
Sex: Female, Male(Participants)Clopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High DoseTotal
Female17021756167117426871
Male461044984596451118215
Region of Enrollment
Region of Enrollment(participants)Clopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High DoseTotal
Argentina182159162174677
Australia971009695388
Austria41353540151
Belgium55615953228
Brazil2922752702881125
Bulgaria111122125112470
Canada3493793733471448
Chile95858290352
China5104925005152017
Croatia114145144114517
Czech Republic2572752772581067
Estonia10012
Finland132127127132518
France177163165175680
Germany4714504534701844
Greece2021232185
India6586506456462599
Ireland2413152375
Israel2862722752821115
Italy232260258231981
Korea, Republic of161149152165627
Latvia1616151562
Lithuania26313028115
Malaysia29393928135
Mexico1617191769
Netherlands46484846188
New Zealand36312929125
Poland3653223253621374
Romania47303348158
Russian Federation132137138131538
Singapore1013151048
Slovakia93848392352
South Africa2414142375
Spain2642762832631086
Sweden101191040
Switzerland51646448227
Turkey79969478347
United Kingdom28293428119
United States7757637597653062
Qualifying condition
Qualifying condition(participants)Clopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High DoseTotal
Suspected Unstable Angina (UA)18091771175718777214
Suspected MI without ST elevation (NSTEMI)266226622668253910531
MI with ST elevation (STEMI)18391817183918327327
Missing243514
Intended PCI performed
Intended PCI performed(participants)Clopidogrel 300/75/75 mg + ASA Low DoseClopidogrel 300/75/75 mg + ASA High DoseClopidogrel 600/150/75 mg + ASA Low DoseClopidogrel 600/150/75 mg + ASA High DoseTotal
Yes437743264262429817263
No19351928200519557823
08

Study locations

38 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Buenos Aires, Argentina
  • sanofi-aventis Australia & New Zealand administrative office
    Macquarie Park, Australia
  • Sanofi-Aventis Administrative Office
    Vienna, Austria
  • Sanofi-Aventis Administrative Office
    Diegem, Belgium
  • Sanofi-Aventis Administrative Office
    Sao Paulo, Brazil
  • Sanofi-Aventis Administrative Office
    Sofia, Bulgaria
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Santiago de Chile, Chile
  • Sanofi-Aventis Administrative Office
    Beijing, China
  • Sanofi-Aventis Administrative Office
    Zagreb, Croatia
  • Sanofi-Aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-Aventis Administrative Office
    Tallinn, Estonia
  • Sanofi-Aventis Administrative Office
    Helsinki, Finland
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Athens, Greece
  • Sanofi-Aventis Administrative Office
    Mumbai, India
  • Sanofi-Aventis Administrative Office
    Dublin, Ireland
  • Sanofi-Aventis Administrative Office
    Natanya, Israel
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Seoul, Korea, Republic of
  • Sanofi-Aventis Administrative Office
    Riga, Latvia
  • Sanofi-Aventis Administrative Office
    Vilnius, Lithuania
  • Sanofi-Aventis Administrative Office
    Kuala Lumpur, Malaysia
  • Sanofi-Aventis Administrative Office
    Mexico, Mexico
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Warszawa, Poland
  • Sanofi-Aventis Administrative Office
    Bucuresti, Romania
  • Sanofi-Aventis Administrative Office
    Moscow, Russian Federation
  • Sanofi-Aventis Administrative Office
    Singapore, Singapore
  • Sanofi-Aventis Administrative Office
    Brastislava, Slovakia
  • Sanofi-Aventis Administrative Office
    Midrand, South Africa
  • Sanofi-Aventis Admnistrative Office
    Madrid, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
  • Sanofi-Aventis Administrative Office
    Guildford, Surrey, United Kingdom
09

References and documents

Publications

  • CURRENT-OASIS 7 Investigators; Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010 Sep 2;363(10):930-42. doi: 10.1056/NEJMoa0909475. Erratum In: N Engl J Med. 2010 Oct 14;363(16):1585. PubMed 20818903 ↗
  • Fuster V. Fine-tuning therapy for acute coronary syndromes. N Engl J Med. 2010 Sep 2;363(10):976-7. doi: 10.1056/NEJMe1008891. No abstract available. PubMed 20818910 ↗
  • Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010 Oct 9;376(9748):1233-43. doi: 10.1016/S0140-6736(10)61088-4. PubMed 20817281 ↗
  • Stone GW. Acute coronary syndromes: finding meaning in OASIS 7. Lancet. 2010 Oct 9;376(9748):1203-5. doi: 10.1016/S0140-6736(10)61262-7. No abstract available. PubMed 20817280 ↗
  • Bossard M, Gao P, Boden W, Steg G, Tanguay JF, Joyner C, Granger CB, Kastrati A, Faxon D, Budaj A, Pais P, Di Pasquale G, Valentin V, Flather M, Moccetti T, Yusuf S, Mehta SR. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease. Heart. 2021 Nov;107(21):1739-1747. doi: 10.1136/heartjnl-2020-318045. Epub 2021 Jan 27. PubMed 33504513 ↗
  • Bossard M, Granger CB, Tanguay JF, Montalescot G, Faxon DP, Jolly SS, Widimsky P, Niemela K, Steg PG, Natarajan MK, Gao P, Fox KAA, Yusuf S, Mehta SR. Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2017 Nov 3;6(11):e006577. doi: 10.1161/JAHA.117.006577. PubMed 29101117 ↗
  • Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S; CURRENT-OASIS 7 Steering Committee. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J. 2008 Dec;156(6):1080-1088.e1. doi: 10.1016/j.ahj.2008.07.026. Epub 2008 Nov 1. PubMed 19033002 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2006
First posted
Jun 9, 2006
Start
Jun 2006
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Oct 7, 2010
Last update
Nov 18, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00335452
Lead sponsor
Sanofi
First posted
Jun 9, 2006
Start date
Jun 2006
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Oct 7, 2010
Last update
Nov 18, 2010

Study contacts

Shamir MEHTA, MD
principal investigator · Hamilton General Hospital, McMaster University, CANADA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion